Summary of the Research: New Antibody Targets Bacterial Sugar to Fight Drug-Resistant Infections
This research details the advancement of a novel antibody that targets a unique bacterial sugar, pseudaminic acid, offering a promising new approach to combatting drug-resistant bacterial infections. Here’s a breakdown of the key points:
* The Problem: Multidrug-resistant bacteria, like Acinetobacter baumannii, pose a significant threat in healthcare settings, often resisting even last-line antibiotics.
* The Innovation: Researchers created a “pan-specific” antibody that recognizes pseudaminic acid, a sugar found only on the surface of many hazardous bacteria. Because humans don’t produce this sugar, the antibody specifically targets bacteria without harming healthy cells.
* How it Works:
* The team synthesized the bacterial sugar in the lab to understand its structure.
* This knowledge allowed them to design an antibody that binds to the sugar with high specificity.
* In mouse studies, the antibody successfully cleared Acinetobacter baumannii infections.
* Passive Immunotherapy: This antibody is designed for passive immunotherapy – providing patients with ready-made antibodies to quickly fight infection, rather than relying on the body’s own immune response. This could be used for both treatment and prevention, notably in vulnerable hospital patients.
* Broader Implications: The antibody also provides a tool to study bacterial virulence and develop better diagnostics.
* Future Plans: the team aims to develop this antibody into a clinical treatment for multidrug-resistant A. baumannii within the next five years, supported by the new Australian Research Council Center of Excellence for Advanced Peptide and Protein Engineering.
Key Researchers Involved:
* Professor Richard Payne (University of Sydney) – Co-lead and director of the new ARC Centre of Excellence.
* Professor Ethan goddard Borger (WEHI) – Co-lead.
* Associate Professor Nichollas Scott (University of Melbourne & Peter Doherty Institute) – Contributed to understanding bacterial virulence.
This research represents a significant step forward in the fight against antimicrobial resistance by targeting a unique bacterial vulnerability.
Related reading